![Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), etc Stock Photo - Alamy Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), etc Stock Photo - Alamy](https://c8.alamy.com/comp/DXB96C/cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-DXB96C.jpg)
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), etc Stock Photo - Alamy
![Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-017-10368-0/MediaObjects/41598_2017_10368_Fig1_HTML.jpg)
Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports
![Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-018-0268-9/MediaObjects/41375_2018_268_Fig1_HTML.png)
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia
Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2 | PLOS ONE
![Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Vector - Illustration of arabinofuranosyl, cancer: 187174096 Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Vector - Illustration of arabinofuranosyl, cancer: 187174096](https://thumbs.dreamstime.com/b/cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-treatment-acute-myeloid-leukemia-aml-acute-lymphocytic-187174096.jpg)
Cytarabine Cytosine Arabinoside, Ara-C Chemotherapy Drug Molecule. Used in Treatment of Acute Myeloid Leukemia AML, Acute. Stock Vector - Illustration of arabinofuranosyl, cancer: 187174096
![Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells - Journal of Lipid Research Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells - Journal of Lipid Research](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/09ad549b-c4e8-4dac-bbe4-6edf8dc23921/gr1_lrg.jpg)
Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells - Journal of Lipid Research
![Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0891584918307457-fx1.jpg)
Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function - ScienceDirect
![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig5_HTML.png)
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Cytarabine as Chemotherapy Literature Cited Future Treatment of Cytarabine Background: Acute Myeloid Leukemia Mechanism of Actio
![Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-52703-7/MediaObjects/41598_2019_52703_Fig1_HTML.png)
Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports
Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
![Vector Art - Cytarabine (cytosine arabinoside, ara-c) chemotherapy drug molecule. used in treatment of acute myeloid leukemia (aml), acute lymphocytic leukemia (all) and lymphoma. Clipart Drawing gg75682591 - GoGraph Vector Art - Cytarabine (cytosine arabinoside, ara-c) chemotherapy drug molecule. used in treatment of acute myeloid leukemia (aml), acute lymphocytic leukemia (all) and lymphoma. Clipart Drawing gg75682591 - GoGraph](https://comps.gograph.com/cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-in-treatment-of-acute-myeloid-leukemia-aml-acute-lymphocytic-leukemia-all-and-lymphoma_gg75682591.jpg)
Vector Art - Cytarabine (cytosine arabinoside, ara-c) chemotherapy drug molecule. used in treatment of acute myeloid leukemia (aml), acute lymphocytic leukemia (all) and lymphoma. Clipart Drawing gg75682591 - GoGraph
![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig3_HTML.png)
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
![Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2d468310-fc98-4a48-9e6a-b466641b7209/gr1_lrg.gif)
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology
![Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers | HTML Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers | HTML](https://www.mdpi.com/cancers/cancers-13-00966/article_deploy/html/images/cancers-13-00966-g001.png)